Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011.

Business Wire • Feb 17, 2026

Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%.

24/7 Wall Street • Feb 16, 2026

Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 319.2% in Janux Therapeutics (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • Feb 3, 2026

Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced that William Go, M.D., Ph.D., has been appointed Chief Medical Officer, effective January 26, 2026. Dr. Go succeeds Zachariah McIver, D.O., Ph.D., who will be leaving th.

Business Wire • Jan 26, 2026

JANX Enters Global Oncology Collaboration With BMY, Stock Rises

Janux Therapeutics struck a global licensing deal for its tumor-activated platforms, sending shares higher and expanding its reach in solid tumors.

Zacks Investment Research • Jan 23, 2026

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. Under the terms of the agreement, th.

Business Wire • Jan 22, 2026

Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug

Janux Therapeutics said on Thursday it has entered a collaboration with Bristol Myers Squibb ​to develop a new cancer treatment, ‌sending its shares up more than 12% in premarket trading.

Reuters • Jan 22, 2026

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million

Janux Therapeutics, Inc. (NASDAQ: JANX) on Thursday announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb Co. (NYSE: BMY).

Benzinga • Jan 22, 2026

Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study

SAN DIEGO--(BUSINESS WIRE)--Janux provided a program update on its Phase 1 study of JANX008, an EGFR-targeted TRACTr, following Phase 1a completion and cohort expansion.

Business Wire • Dec 23, 2025

Options Exercise: Janux Executive Sells 16,665 Shares for $501,000

Meyer Andrew Hollman, Chief Business Officer at Janux Therapeutics (JANX 1.70%), exercised 16,665 options and immediately sold the resulting shares for a transaction value of approximately $501,000 on October 28, 2025, according to a recent SEC Form 4 filing.

The Motley Fool • Dec 4, 2025